The Thai Pharma Import Lane: Multinational Brands, Thai-FDA Pathway, and Generic Substitution

Questions this report answers

What's the structural import-vs-domestic split? Per Bangkok Post, Krungsri Research triangulation: Thai pharma market THB 220-280B🔒 annual; ~60%🔒 multinational-imported branded-pharma plus ~40%🔒 Thai-domestic-generic. Major multinational operators: Pfizer Thailand, Sanofi, Novartis, Roche, Bayer, Boehringer Ingelheim, AstraZeneca, Merck (US-MSD), J&J, GSK, Eli Lilly, BMS — operate via Thai-licensed entities or Thai-licensee distribution.^[1]

Who are the Thai-domestic-generic operators? GPO (Government Pharmaceutical Organization, state-owned, structural Thai-domestic anchor), Siam Bioscience (Crown-Property Bureau-owned, COVID-19 vaccine, biologics, biosimilar pipeline), Berlin Pharmaceutical Industry, Thai Otsuka, Olic, Siam Pharmaceutical, Greater Pharma. NLEM National List of Essential Medicines drives public-hospital procurement substitution to generic-equivalent.^{[2, 3]}

What's the regulatory and CL precedent? Thai FDA Drug Act B.E. 2510 (1967, revised) approval pathway requires New Drug Application, product registration, GMP compliance. CL (Compulsory Licensing) precedent 2007-2008 for HIV ARVs (efavirenz) drove Thai government generic-substitution campaign — material precedent for HIV / cancer / heart-disease essential-medicines pricing leverage.^{[4, 5]}

Executive summary

Thai pharma THB 220-280B🔒 annual; ~60%🔒 multinational-imported, ~40%🔒 Thai-domestic-generic. Major multinational: Pfizer, Sanofi, Novartis, Roche, Bayer, Boehringer Ingelheim.^[1]

Thai-domestic-generic: GPO (state), Siam Bioscience (Crown-Property), Berlin Pharmaceutical, Olic. DKSH, Zuellig wholesale distribution leaders.^{[2, 3]}

Thai FDA Drug Act 1967, NLEM essential-medicines list. CL HIV-ARV 2007-2008 precedent. Watch CL-precedent revival and biosimilar-approval evolution.^{[4, 5]}

Thai pharma market structure

Thai pharma market trajectory (THB billion, 2020-2025E)

Multinational rankings and product-mix shifts

Per market-research triangulation (Reportlinker, Grand View Research): Novartis ranked as the highest-revenue private multinational pharma company in Thailand in 2023, followed by Mega Lifesciences (Thai-headquartered Asian distributor), Boots Retail Pharmacy, GlaxoSmithKline, Pfizer, and AstraZeneca. The category continues to lean ~60%🔒 on multinational brand, but the mix is shifting fast toward biologics, biosimilars, and oncology therapies — where Thai-domestic capacity is the structural watch.^{[1, 7]}

Thailand's overall pharmaceutical market is projected to grow at ~7.7%🔒 CAGR from 2025 to 2030 per Grand View Research; biologics and biosimilars carry materially higher CAGR than small-molecule generics. Thai FDA released biologics guidelines around 2010 aligned with WHO and ASEAN harmonisation, and the country's first biosimilar guidelines followed in October 2013. The biosimilar-approval framework continues to mature; Siam Bioscience and the PTT-GPO oncology JV are the two visible domestic biosimilar plays.^{[3, 8]}